Your browser doesn't support javascript.
loading
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes.
Tyan, Kevin; Bae, Ji Eun; Lorch, Jochen H; Margalit, Danielle N; Tishler, Roy B; Huynh, Mai Anh; Jo, Vickie Y; Haddad, Robert I; Chau, Nicole G; Hanna, Glenn J; Schoenfeld, Jonathan D.
  • Tyan K; Harvard Medical School, Boston, Massachusetts, USA.
  • Bae JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Lorch JH; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Margalit DN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Tishler RB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Huynh MA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Jo VY; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Haddad RI; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Chau NG; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Hanna GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Schoenfeld JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Head Neck ; 44(3): 722-734, 2022 03.
Article en En | MEDLINE | ID: mdl-34927307
ABSTRACT

BACKGROUND:

There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC).

METHODS:

Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1-5 lesions) at any point during follow-up.

RESULTS:

There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14-0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02-0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07-0.71).

CONCLUSIONS:

There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Adenoide Quístico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Adenoide Quístico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article